Holen Sie sich die Stockscreener-App
15.52
1.04%
-0.27
Schlusskurs vom Vortag:
$15.79
Offen:
$15.6
24-Stunden-Volumen:
45,803
Relative Volume:
0.18
Marktkapitalisierung:
$2.01B
Einnahmen:
$65.48M
Nettoeinkommen (Verlust:
$-94.46M
KGV:
-21.04
EPS:
-0.7375
Netto-Cashflow:
$-71.18M
1W Leistung:
+0.48%
1M Leistung:
+5.08%
6M Leistung:
+4.66%
1J Leistung:
+43.61%
1-Tages-Spanne:
$15.35
$15.66
1-Wochen-Bereich:
$15.19
$16.06
52-Wochen-Spanne:
$9.88
$21.50
Mesoblast Ltd Adr Stock (MESO) Company Profile
Firmenname
Mesoblast Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare MESO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
15.54 | 2.04B | 65.48M | -94.46M | -71.18M | -0.7375 |
VRTX
Vertex Pharmaceuticals Inc
|
428.62 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
719.02 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.88 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.12 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.57 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-12-23 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-24 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-08-29 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-23 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-07 | Herabstufung | Maxim Group | Buy → Hold |
| 2023-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | Eingeleitet | William Blair | Outperform |
| 2022-12-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-06 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-07 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-12-22 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-12-04 | Herabstufung | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | Bestätigt | Maxim Group | Buy |
| 2020-05-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-31 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-03-22 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2017-06-08 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Mesoblast Ltd Adr Aktie (MESO) Neueste Nachrichten
Mesoblast LimitedDepositary Receipt (MESO) price target decreased by 14.96% to 15.33 - MSN
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - GlobeNewswire Inc.
Mesoblast acquires CAR technology license from Mayo Clinic - Investing.com
FDA clears Mesoblast DMD trial for Ryoncil in children - Investing.com
Mesoblast drops after Ryoncil sales data for March quarter - Seeking Alpha
MESO Ignites 10% Surge: A Biotech Spark Ignited Without a Visible Fuse - Bitget
Philip Krause details Mesoblast (NASDAQ: MESO) share and option holdings - Stock Titan
Mesoblast issues 5 million unquoted warrants as fee for US$50 million convertible note facility - MSN
Mesoblast Ltd Stock (ISIN: AU000000MSB8) Faces Pressure as Director Buys Signal Confidence Amid Anal - AD HOC NEWS
Gregory George beneficial owner at Mesoblast (OTC: MEOBF) with 22.36% stake - Stock Titan
MEOBF SEC FilingsMesoblast 10-K, 10-Q, 8-K Forms - Stock Titan
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Sahm
Earnings call transcript: Mesoblast’s strong Q1 2026 performance boosts outlook - Investing.com
FARM 51 GROUP S.A.ZY -,1.XFRA: MWBMUHANDELSUNTERBRECHUNGTEIL 5 - aktiencheck.de
Mesoblast stock reaches 52-week high at 21.05 USD - Investing.com
Mesoblast stock reaches 52-week high at 21.05 USD By Investing.com - Investing.com India
Mesoblast announces board leadership changes as company evolves - Investing.com South Africa
Mesoblast Issues 5 Million Unquoted Warrants as Fee for US$50 Million Convertible Note Facility - TipRanks
Mesoblast Shares (ASX:MSB) Stall at Resistance After Recent Rally - thebull.com.au
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - TradingView
Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - inkl
Jefferies upgrades Mesoblast stock to Buy on strong Ryoncil sales - Investing.com
Mesoblast rides early ryoncil® momentum, tightens cash discipline, and prepares for next growth phase - Proactive financial news
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket - Benzinga
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mesoblast secures up to US$50m in fresh funding through convertible note agreements - Biotech Dispatch
Mesoblast Secures Up To US$50 Mln In Convertible Note Agreements With Key Investors - Nasdaq
Canaccord Genuity initiates Mesoblast stock with Buy rating on cell therapy potential - Investing.com
Mesoblast stock soars after reporting first Ryoncil sales - Investing.com
Mesoblast Ltd (MSB) Stock Forecast & Analyst Ratings - Moomoo
Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Sahm
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Benzinga
All Markets & Instruments Available to Trade - Capital.com
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Mesoblast After Approval: Stock Is Buoyant Now, But Unpredictable Overall (NASDAQ:MESO) - Seeking Alpha
Mesoblast Finally Gets Its Approval In GVHD: Where Now? (NASDAQ:MESO) - Seeking Alpha
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential (NASDAQ:MESO) - Seeking Alpha
MESOMesoblast Ltd ADR Short Interest - Finviz
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - TradingView — Track All Markets
symbol__ Stock Quote Price and Forecast - CNN
Mesoblast Ltd Share Price ADR Each Representing 10 Ord Shares SPON - Hargreaves Lansdown
Recent Insider BuyingStock ScreenerSnapshot - Finviz
What is the current Price Target and Forecast for Mesoblast Limited (MESO) - Zacks Investment Research
Finanzdaten der Mesoblast Ltd Adr-Aktie (MESO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):